Acne Vulgaris: What to Do When Multimodal Topical Therapy Has Not Achieved IGA Success at 12 Weeks

Clinical scenario

This protocol applies to patients with acne vulgaris whose disease has not responded sufficiently to an initial course of multimodal topical therapy. The expected milestones — Investigator's Global Assessment (IGA) success and meaningful reduction in both inflammatory and noninflammatory lesion counts — were not reached at the 12-week evaluation.

Prior treatment & failure condition

The first-line approach was multimodal topical therapy combining multiple mechanisms of action. This regimen did not achieve the defined targets of IGA success and adequate lesion-count reduction at 12 weeks. Escalation to the next treatment line is therefore indicated.

Next-line treatment approach

The protocol introduces a systemic antibiotic from the tetracycline class, used alongside ongoing topical therapy — not as monotherapy. The systemic component is limited to the shortest effective duration. The full treatment algorithm, including agent selection and all supporting recommendations, is available in the structured protocol.

Treatment goal: Acne improvement with IGA success at 4 months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaad.2023.12.017

When treating acne with systemic antibiotics, we recommend concomitant use of BP and other topical therapies as a good practice statement to decrease risk of antibiotic resistance and to limit the duration of systemic antibiotic exposure.
Oral antibiotics should not be used as monotherapy for acne treatment.
Systemic antibiotic use should also be limited to the shortest duration possible, typically no more than 3–4 months, as recommended by international guidelines.
Compared to vehicle at 4 months, a greater proportion of patients treated with doxycycline achieved IGA success in 2 RCTs (RR, 1.80 [1.17, 2.77]).

View source ↗